Trial Profile
A Phase Ib Clinical Trial Evaluating DCVax-Direct, Autologous Activated Dendritic Cells for Intratumoral Injection, in Patients With Unresectable Brain Metastases From Breast- or Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2020
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
- Indications Brain metastases
- Focus Adverse reactions
- Sponsors Northwest Biotherapeutics
- 04 Jun 2019 According to a Northwest Biotherapeutics media release, this trial has been cleared by FDA.
- 27 Aug 2018 New trial record